Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Tuberculosis

  Free Subscription


29.04.2019

1 Am J Respir Crit Care Med
4 Antimicrob Agents Chemother
1 Eur Respir J
1 J Clin Microbiol
1 J Infect Dis
1 Lancet Glob Health
1 Lancet Respir Med
3 PLoS Med
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. KRANZER K, Kalsdorf B, Heyckendorf J, Andres S, et al
    New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?
    Am J Respir Crit Care Med. 2019 Apr 26. doi: 10.1164/rccm.201902-0260.
    PubMed     Text format    


    Antimicrob Agents Chemother

  2. VAN DEN ELSEN SHJ, Sturkenboom MGG, Akkerman OW, Manika K, et al
    Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00384.
    PubMed     Text format     Abstract available

  3. GHODOUSI A, Tagliani E, Karunaratne E, Niemann S, et al
    Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype comprised of overlapping MIC distributions with different underlying resistance mechanisms.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00092.
    PubMed     Text format     Abstract available

  4. IACOBINO A, Giannoni F, Pardini M, Piccaro G, et al
    The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant Mycobacterium tuberculosis in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00273.
    PubMed     Text format     Abstract available

  5. LUN S, Tasneen R, Chaira T, Stec J, et al
    Advancing the therapeutic potential of indoleamides for tuberculosis.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00343.
    PubMed     Text format     Abstract available


    Eur Respir J

  6. MIGLIORI GB, Nardell E, Yedilbayev A, D'Ambrosio L, et al
    Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
    Eur Respir J. 2019 Apr 25. pii: 13993003.00391-2019.
    PubMed     Text format     Abstract available


    J Clin Microbiol

  7. MTAFYA B, Sabiiti W, Sabi I, John J, et al
    Molecular bacterial load assay (MBLA) concurs with culture on the NaOH-induced Mycobacterium tuberculosis loss of viability.
    J Clin Microbiol. 2019 Apr 24. pii: JCM.01992-18. doi: 10.1128/JCM.01992.
    PubMed     Text format     Abstract available


    J Infect Dis

  8. BLUMENTHAL MJ, Schutz C, Barr D, Locketz M, et al
    The contribution of KSHV to mortality in hospitalized HIV-infected patients being investigated for tuberculosis in South Africa.
    J Infect Dis. 2019 Apr 20. pii: 5475547. doi: 10.1093.
    PubMed     Text format     Abstract available


    Lancet Glob Health

  9. SEUNG KJ, Hewison C
    Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.
    Lancet Glob Health. 2019 Apr 17. pii: S2214-109X(19)30186.
    PubMed     Text format    


    Lancet Respir Med

  10. MUSHTAQ A
    Tuberculosis in diabetes: insidious and neglected.
    Lancet Respir Med. 2019 Apr 16. pii: S2213-2600(19)30119.
    PubMed     Text format    


    PLoS Med

  11. CHURCHYARD GJ, Swindells S
    Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB.
    PLoS Med. 2019;16:e1002787.
    PubMed     Text format     Abstract available

  12. WARSINSKE H, Vashisht R, Khatri P
    Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures.
    PLoS Med. 2019;16:e1002786.
    PubMed     Text format     Abstract available

  13. VEKEMANS J, O'Brien KL, Farrar J
    Tuberculosis vaccines: Rising opportunities.
    PLoS Med. 2019;16:e1002791.
    PubMed     Text format     Abstract available


    PLoS One

  14. JO EJ, Park S, Lee KM, Kim I, et al
    Time to appropriate treatment in patients with multidrug-resistant tuberculosis in South Korea: Are we still in 2010?
    PLoS One. 2019;14:e0216084.
    PubMed     Text format     Abstract available

  15. OGA-OMENKA C, Zarowsky C, Agbaje A, Kuye J, et al
    Rates and timeliness of treatment initiation among drug-resistant tuberculosis patients in Nigeria- A retrospective cohort study.
    PLoS One. 2019;14:e0215542.
    PubMed     Text format     Abstract available

  16. MUKHTAR F, Butt ZA
    Risk of adverse treatment outcomes among new pulmonary TB patients co-infected with diabetes in Pakistan: A prospective cohort study.
    PLoS One. 2018;13:e0207148.
    PubMed     Text format     Abstract available

  17. TESFAYE B, Alebel A, Gebrie A, Zegeye A, et al
    The twin epidemics: Prevalence of TB/HIV co-infection and its associated factors in Ethiopia; A systematic review and meta-analysis.
    PLoS One. 2018;13:e0203986.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: